PD1 blockade enhances K+channel activity, Ca2+signaling, and migratory ability in cytotoxic T lymphocytes of patients with head and neck cancer

• DOI: 10.1136/jitc-2020-000844
• Publication Date: 2020-10-15T21:51:39Z
• Authors: Hannah S Newton; Vaibhavkumar S Ga...; Ameet A Chimote; Maria A Lehn; Sarah M Palackdharry; Benjamin H Hinrichs; Roman Jandarov; David Hildeman; Edith M Janssen; Trisha M Wise-Draper; Laura Conforti
• Keywords: Clinical/Translational Cancer Immunotherapy; Male; 0301 basic medicine; Programmed Cell Death 1 Receptor; Neoplasms. Tumors. Oncology. Including cancer and carcinogens; Middle Aged; 3. Good health; 03 medical and health sciences; Head and Neck Neoplasms; Potassium; Humans; Calcium; Female; Immunotherapy; RC254-282; Aged; Signal Transduction; T-Lymphocytes, Cytotoxic

Immunotherapy has emerged as a promising treatment modality for head and neck squamous cell carcinoma (HNSCC). Pembrolizumab, an anti-programmed death 1 antibody, is immunotherapy agent currently approved metastatic HNSCC curative intent clinical trials. Although responses to pembrolizumab are promising, many patients fail respond. However, it well known that T cytotoxicity chemotaxis critically important in the elimination of tumors. These functions depend on ion channel activity downstream Ca